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Abstract
The Hair Follicle (HF) is a vital component of mammalian skin and represents a unique, highly regenerative 
system that undergoes phases of rapid growth, regression, and resting periods. The hair cycling is of profound 
clinical relevance since majority of the hair growth disorders occur as a result of cycle changes. The influence of 
many molecules governing the formation of HF has been investigated and many of important cycle mediators have 
been identified. Cellular and molecular events during cycling are controlled by a network of sequential activation of 
autocrine, paracrine and endocrine signaling pathways. This implies variations in the expression or activity of the 
Wnt family molecules, Fibroblast Growth Factor (FGF), Transforming Growth Factor β (TGF-β), Hedgehog pathway, 
β-Catenin pathway, noggin, transcription factor Stat3, Epidermal Growth Factor (EGF), Insulin Growth Factor-1 (IGF-
1), Vascular Endothelial Growth Factor (VEGF), Thyrotropin Releasing Hormone (TRH), Polyamine, Spermidine, 
Neurotrophins (NT3, NT4), prolactin, retinoids, Bone Morphogenetic Protein 4 (BMP4), cathepsin L, 17-β estradiol, 
dihydrotestosterone and many others. Despite considerable progress in this area, the key elements of cycle control 
have not been identified. Therefore, for the most common hair disorders several agents are available, even none 
of these is curative or preventive. The one of the prime challenges of hair research is a better understanding of the 
molecular controls of hair cycling and developing drug which would effectively manipulate the cycle. Future therapy 
strategies will be based on new and better knowledge about the HF biology. Until than, alopecia areata, telogen 
effluvium and androgenetic alopecia, will remain unsolved medical problems.
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Introduction
The Hair Follicle (HF) is a vital component of mammalian skin. 
Thick scalp hair gives protection from actinic damage, while specialized 
nasal hairs, eyebrows and eyelashes have some environmental protective 
role. HF is also involved in sensory perception as a functionally distinct 
mechanosensory organ, giving the wide tactile sensation range of 
covered skin surface [1]. Beside the sensory activity role, hair exerts 
a function of thermoregulation, physical protection, tissue renewal 
and regeneration, and serves as an instrument of psychosocial 
communication [2].
 Production of a hair is the primary and the most important function 
of HF. Hair growth does not take place continuously, but in a strictly 
defined cyclic model that includes periodic regeneration of follicles 
[3]. A synchronized cycle, seen in mammals, is preparing hair coat 
for environmental seasonal changes. The purpose of unsynchronized 
cycle which is seen in human species is not so obvious, but may include 
cleaning the skin surface of debris and parasites, and secretion of some 
chemical compounds via trichocytes [4].
Hair growth disorders can be attributed, at large, to a changes in the 
normal dynamic behaviour of the HF [5]. Since the cycle is regulated 
by various hormones and growth factors produced both inside and 
outside the follicles, even small environmental changes may lead to a 
shortening of the anagen, catagen phase induction, and increasing the 
number of telogen follicles [6].
 Telogen effluvium, Androgenetic Alopecia (AGA), and Alopecia 
Areata (AA), the frequent hair loss disorders in clinical practice, 
exemplify how discrete cycling changes translate into significant 
clinical problems. Therefore, knowing the hair cycle is necessary for 
understanding the pathogenesis of hair diseases in general. Current 
hair treatment strategies are symptomatic and nonspecific so nowadays 
researches aim at developing new, targeted methods. Future strategies 
planning specific hair disorders therapy will be based on new and better 
knowledge about the HF biology. 
Hair Follicle: A Complex Miniorgan
The hair follicle is perfect and clinically relevant model for biology 
research. It represents a complex miniorgan that consists of multiple 
different cell populations which are distinct in their location, function 
and protein expression characteristics [4,7,8]. The HF is also a uniquely 
dynamic system that undergoes continuous cycling throughout adult 
life during which elements of its own morphogenesis are recapitulated 
[9]. This miniature organ during the normal human lifespan 
regenerates itself more than 8 to 10 times [2,10]. The transformation 
process of HF during the cycle arises under the dictates of an enigmatic 
oscillator system, “the hair cycle clock’’, and happens simultaneously 
with changes in the sebaceous gland, perifollicular dermis and subcutis 
[11-13]. 
Regarding the origin of its structures, the mature HF can be divided 
into the mesenchymal part, consisting of the Dermal Papilla (DP) with 
connective tissue sheath, and the epithelial part, including transient 
amplifying cells of the hair matrix that envelope the DP, hair shaft, inner 
root sheath and outer root sheath. Coordination between epithelial and 
mesenchymal portions of HF as well as bi-directional communication 
between the pilosebaceous unit and its innervation and vasculature is 
needed to maintain the cyclic hair follicle growth [14-16].
Functionally, HF can be divided into upper permanent part and 
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deep lower part (including the hair bulb) which is subject of great 
changes during the cycle. Morphologically, the two parts are divided 
by a line that lies below the “bulge zone”, an eminent structure at the 
site of the arrector pili muscle attachment. Bulge zone is the lowest part 
of the permanent HF segment and it is histological evident as unilateral 
thickening of the outer root sheath [17]. It is inhabited by epithelial 
stem cells, precursors of melanocytes, mast cells and Langerhans cells. 
Thanks to bulge stem cells, HF regenerates itself [18,19].
Stem Cells (SCs), which reside in the adult HF, are the skin’s elixir 
for regenerating hair, but also for maintaining tissue homeostasis and 
repairing the epidermis [20]. SCs are nonspecific and pluripotent, 
having the ability to self-renew and differentiate into multiple cell 
types. The classical view of SCs depicts them as slowly cycling, relatively 
undifferentiated cells, with the ability both for self-regeneration and for 
supplying the rapidly dividing progenitor population [9]. Until now, 
melanocytic SCs, mesenchymal SCs, mast cells precursors, immature 
Langerhans cells and neuronal SCs were recognized [21-27].
The Dermal Papilla (DP) functions as the hair signaling center, and 
represents as a pocket of mesenchymal cells that lies at the hair base 
[28-30]. The number of DP cells and their secretory activity determines 
the size of the anagen hair bulb, thickness, length, and the hair shaft 
diameter [31-33]. 
The HF can be considered an essentially autonomous organ as 
it is able to grow after dissection from its neurovascular supply and 
transplantation into another part of the integument [34]. In addition, 
isolated human HF can be maintained in organ culture, exhibiting 
emergent properties of great biological relevance: controlled cell 
proliferation, differentiation, apoptosis and organ regeneration [35,36]. 
Hair Cycle
The hair cycle is traditionally divided into the growth phase 
(anagen I-VI), regression phase (catagen) and resting phase (telogen) 
[2]. Hair loss has recently been recognized as a separate active process 
that is called exogen, while kenogen is a brief interval in which the HF 
remains empty [37].
Anagen phase has significantly higher metabolic activity among 
matrix keratinocytes that produce the hair fiber and inner root sheath. 
It is divided into six subphases defined by specific morphological 
criteria, one of which is called pro-anagen, including phases I to V. 
The met-anagen phase follows, which leads to hair growth on the 
epidermis surface [38]. During the end of the anagen, follicle lies deep, 
firmly anchored in the subcutaneous tissue, while the bulb changes the 
position by moving more superficial, below the insertion of the arrector 
pili muscle. Anagen phase ends with the involution of HF, apoptosis 
and terminal differentiation [39-41].
Catagen is the time of involution. It is a short transitional phase 
of cycle between anagen and telogen, which lasts between two and 
four weeks. In this phase follicle undergoes a series of morphological 
and molecular changes that are associated with apoptosis. The first 
sign of involution is termination of bulb melanin production. Matrix 
melanocytes stop producing melanin and absorb dendrites, and 
keratinocytes cease proliferation and undergo terminal differentiation 
[5]. During catagen, the population of stem cells located lateral to the 
dermal papilla is spared from apoptosis, allowing the reproliferation in 
the early anagen [33].
After regression, the follicle enters the telogen phase, which is 
expressed by relative rest in terms of activation and proliferation. 
Telogen phase lasts three to four months. The hair is no longer firmly 
anchored in the tissue, the link between lower part of hair and follicular 
sac disappears, and the hair falls out. 
Recent researchers have found that the hair loss is controlled; 
active process that significantly differs from inaction during telogen 
[42]. Even the nature of the process is not yet solved; the morphology of 
hair root suggests that this process, called exogen, involves proteolytic 
events among cells in the base of telogen hair [43]. 
Kenogen is interval in which the hair follicle remains empty after 
the telogen hair loss and before the outbreak of a new anagen hair. 
Number of hairs in kenogen increases parallel with the number of 
vellus hair and reducing normal hair cycles, which is the main feature 
of AGA deterioration [44].
Regulation of Hair Cycle
Since the majority of hair growth disorders occur as a result of the 
hair cycle changes, HF cycling is of profound clinical relevance. The 
concept that skin appendage formation at a given location and time is 
the result of interacting stimulatory and inhibitory signals exist for the 
long time; these not only consist of secreted molecules and changes in 
the expression of receptors, but also of changes in tissue biology and 
underlie prominent epigenetic controls [45,46].
By recent theory, the cycling is caused by rhythmic signal 
transducers changes in the bulge zone and dermal papilla region, with 
complex processes that are the consequences of follicular stem cells 
and dermal papilla cells interactions. Although HF ‘system’ is highly 
sensitive to extra-follicular neural and vascular signals thus increasing 
the level of system complexity, basic autonomous clock driving the HF 
cycle reside in the HF itself [10,15,47,48].
In any case, cellular and molecular events during differentiation 
of HF are controlled by a complex network of sequential activation 
of autocrine, paracrine and endocrine signaling pathways. This 
implies variations in the expression or activity of numerous cytokines, 
hormones, neurotransmitters, transcription factors and enzymes in the 
key compartments of HF. 
The development of skin appendage such as hair is regulated by 
signaling molecules of the Wnt family, Fibroblast Growth Factor (FGF), 
transforming growth factor β (TGF-β), and Hedgehog pathways [49]. 
Hair follicle regeneration begins when signals from the mesenchyme-
derived dermal papilla cells reach multipotent epidermal stem cells in 
the bulge region. Key inducers of anagen, the rapid growth hair cycle 
phase, including Wnt family proteins, β-Catenin pathway, noggin, and 
the transcription factor Stat3 [50]. Signal transducer and activator of 
transcription 3 (Stat3) plays critical roles in biological activities and 
contributes to HF growth. Stat3 is a latent cytoplasmic protein that 
conveys signals to the nucleus upon stimulation with IL-6, Epidermal 
Growth Factor (EGF), and many other cytokines/growth factors [51]. 
EGF probably triggers multiplication and proliferation of outer root 
sheath follicle cells that leads to the formation of new hair follicles. 
Another EGF role is probably anagen to catagen transition [52].
Wnt/β-catenin signaling is also known to positively affect 
mammalian hair growth. For example, HF stem cell differentiation is 
inhibited through a cross talk between Wnt/β-catenin and androgen 
signalling in dermal papilla cells from patients with androgenetic 
alopecia [53].
Sonic Hedgehog Proteins (Shh) and Hepatic Growth Factor (HGF) 
furthermore promote anagen development. Upregulation of Shh 
activity functions as a biologic switch that induces resting hair follicles 
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to enter anagen with consequent hair growth. Sonic hedgehog is one of 
the earliest genes found to be expressed in the hair placode. Continuous 
labeling of Shh-expressing cells showed that their progeny, with rare 
exceptions, form all structures in the HF. Shh expression is necessary 
also for the embryonic development of hair follicles [10,54-58].
 The duration of anagen phase prolong Insulin Growth Factor-1 
(IGF-1), Vascular Endothelial Growth Factor (VEGF) and Thyrotropin-
Releasing Hormone (TRH). IGF-1 and IGF-2 are dose-dependent HF 
growth stimulators that also prevent the entry of follicles into catagen. 
It is possible that both of these growth factors are key physiological hair 
cycle regulators. Hypothesis is supported by a noticeable decline in the 
expression of mRNA for IGF-1 during early catagen [59,60].
TRH promotes hair-shaft elongation, prolongs the anagen and 
antagonizes its termination by Transforming Growth Factor-β2 
(TGF-β2) [59]. Human HFs are direct targets of thyroid hormones 
and demonstrate that T3 and/or T4 modulate multiple hair biology 
parameters, ranging from HF cycling to pigmentation. Human scalp 
HFs are both a source and a target of TRH, which operates as a potent 
hair-growth stimulator [59,61].
Important anagen prolongator/catagen inhibitor is also the key 
polyamine-spermidine. Polyamines are multifunctional polycationic 
aliphatic amines which except serving as metabolic and nutrients 
regulators, also have been implicated as mediators of key cell functions, 
such as proliferation, migration and differentiation. Spermidine is a 
potent stimulator of human hair growth and a previously unknown 
modulator of human epithelial stem cell biology [62,63].
Finally, an important role in the regenerating hair follicle, play hair 
follicle stem cell marker nestin, located in the dermal papilla [64].
Anagen is terminated by the concurrent decreasing of anagen 
upholding factors (IGF-1, HGF, FGF-5S) and increasing of hair growth 
inhibitors, like members of the transforming growth factor (TGF- β1, 
TGF- β2), fibroblast growth factor. Inhibition of TGF-β2 activity 
at receptor level significantly impairs the maturation of follicles and 
folliculogenesis [65].
Dickkopf 1 (DKK-1) is involved in anagen-to-catagen transition 
in the hair cycle by regulating the activity of follicular keratinocytes. 
Moreover, it is observed that recombinant human DKK-1 (rhDKK-1) 
blocks canonical Wnt-mediated activation of β-catenin signaling and 
induces the proapoptotic protein Bax, resulting in apoptosis in outer 
root sheath keratinocytes [66]. Besides, the molecular interaction 
between downregulating effectors of TNF-asignalling and keratin 
17 (K17) may be partly responsible for controlling catagen entry by 
regulating the rate of apoptosis [2]. Last decade has revealed a pivotal 
role for the TNF family ligand Ectodysplasin (Eda) in multiple steps of 
hair morphogenesis, from initiation to differentiation. Other members 
of the TNF superfamily such as Rank ligand, lymphotoxins and TNF 
have recently been linked with sp ecific aspects of skin appendage 
biology including hair shaft formation, and hair follicle cycling [49].
Other involved controlling anagen-catagen transformation 
molecules are neurotrophins NT-3, NT-4, as well as prolactin and 
retinoids. Prolactin participates in the regulation of anagen and telogen 
initiation, and is produced by the follicle itself. Recent studies identifie 
PRL as a major, clinically relevant, novel neuroendocrine regulator of 
both human keratin expression and human epithelial stem cell biology 
in situ [10,50,67,68].
The signaling that controls hair cycle resting phase is only partly 
understood. Telogen concurs with major gene activity changes and 
some proteins, like estrogen receptor, are noticeably increased, so this 
phase is not really quiescent as traditionally described. On the contrary 
telogen probably represents a key stage in hair cycle control. 
The follicle in telogen arrest Bone Morphogenetic Protein 4 (BMP4) 
and 17-β estradiol [50]. BMPs are diffusible molecules involved in a 
variety of cellular interactions during development. It is proposed that 
about the stage of terminal division, the balance between BMP and 
BMP-inhibitory signals regulates survival and specification of hair-cell 
precursors [69].
Hair cycle resting phase is regulated also by cyclic epithelial 
Fibroblast Growth Factor (FGF18). Signaling FGF18 is expressed 
in a hair stem cell niche throughout telogen, and that it regulates 
the hair cycle through the non-growth phases. FGF affects follicular 
morphogenesis, participates in the regulation of mitotic activity and 
differentiation. Receptors for this growth factor have been identified in 
the follicular papilla and in the basal layer of epidermal keratinocytes 
[70].
The cycle stage, called exogen, has its own control mechanisms and 
it is presumed that its regulators are protease cathepsin L and Msx-2 
[2].
Regarding hormonal influence, autocrine and paracrine factors 
produced by balding DP cells following Dihydrotestosterone (DHT)-
driven alterations are believed to be key factors involved in male 
pattern baldness. IL-6 is upregulated in balding DP cells compared 
with non-balding DP cells. Dihydrotestosterone-inducible IL-6 inhibits 
elongation of human hair shafts by suppressing matrix cell proliferation 
and promotes regression of hair follicles [71]. 17β-estradiol (E2) 
inhibits hair shaft elongation and anagen prolongation in human 
female occipital hair follicles, whereas in male stimulates hair shaft 
elongation of frontotemporal scalp follicles [50].
In conclusion, even mostly through mouse models studies, our 
knowledge of the HF biology is continuously increasing. The promising 
research approach would be to screen the human HF for the expression 
of yet recognized mammalian clock genes [72].
The Perspectives in Hair Growth Disorders Treatment
It is perfectly clear that a hair growth disorders can be attributed, at 
large, to a changes in the normal dynamic behaviour of the HF. Logical 
conclusion appears that the hair growth disorders could be treated by 
inhibiting premature transition to catagen phase and/or stimulating 
the transition from telogen into the anagen phase. Hovewer, the key 
elements of cycle regulation have not been identified. Although all yet 
recognized molecules offering themselves to be exploited as chemical 
tools for hair disorders treatment, still remains to synthesize drugs 
which would effectively manipulate the cycle [6].
Plenty therapeutic agents have been tried as a potent hair cycle-
modulators with with variable efficacy and safety profiles. These agents 
among others include Cyclosporin A (CsA), topical immunophilin 
ligands, prostaglandin, ezetimibe and simvastatin, minoxidil, retinoids, 
estrogen, adenosin, calcitriol, estradiol, and prednisolon, zinc, and 
candida antigen [73-84].
For the most common hair disorders several agents are currently 
available. The first line of treatment in AGA is still minoxidil, despite of 
low success rate and speculative mechanism of action. The finasteride 
inhibits the production of the male hormone dihydrotestosterone but 
as with minoxidil, one’s previous degree of hair loss returns when 
finasteride is discontinued [85]. Treatment options for female AGA 
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also include the androgen receptor antagonists spironolactone and 
cyproterone acetate [86,87]. Considering AA treatment, except for 
topical immunotherapy and corticosteroids, there are few published 
studies on long-term therapeutic success of avaliable therapeutic 
agents. Biologics have also been tried, but shown either development 
of AA or complete failure to respond to different TNF alpha inhibitors, 
including adalimumab, infliximab and etanercept [88-91].
Regarding perspectives, a studies have focused on various 
innovative pharmacologic targets, but also on some well known 
molecules. The role of prolactin receptor antagonists, as well as the 
regulators of thyroid hormones, deserves to be the subject of further 
research . Also, the relation between vitamin D levels, vitamin D 
receptor and hair cycling, specifically anagen initiation, represent an 
attractive area of research nowdays [92].
 New drug treatment opportunities for AA also include use of 
drugs that block the NKGD-activating ligand and NKG2D receptor 
interaction, halt activated T cells, or modificate the cytokine network 
[93].
 Calcitonin Gene-Related Peptide (CGRP) may award relative 
protection from interferon-γ-induced collapse of human hair follicle 
immune privilege and might help to retard AA progression [94]. 
Also, Fuzzy (fz), an autosomal recessive mutation that is involved in 
controlling catagen and anagen initiation, is an exciting target that 
maybe drives HF cycling [95].
 Recently, autologous platelet-rich plasma (PRP) has attracted 
attention in plastic surgery and dermatology, for its ability to promote 
wound healing and to increase hair density [96].
 The new studies also make a substantial contribution towards the 
development of transplantation therapy for skin and skin appendages, 
even the autologous transplantation of HF is already an accepted 
treatment for AGA [97].
There are also numerous ongoing studies, that explore the 
possibilities of using stem cells in treating hair growth disorders. 
Theoretically it would be possible to regenerate HF cultivating 
autologous dermal papilla cells and transplanting them to the hairless 
skin. This hypothetical process of breeding HF would enable the 
efficient compensation of the lost hair when all other options fail [98].
Conclusion
Recent years have witnessed a considerable progress in the research 
focused on treatment of hair disorders, but with limited success. 
Therefore, one of the prime challenges of modern hair research is a 
more profound understanding of the molecular controls of hair follicle 
cycling. Common diseases such as alopecia areata, telogen effluvium 
and AGA, until than will remain the unsolved medical problems.
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